(Q34297725)

1 August 2017

1 reference

title

Comparative effects of cilostazol and other therapies for intermittent claudication (English)

1 reference

1 August 2017

1 reference

D L Dawson

1

1 reference

PubMed ID

11434896

1 August 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

American Journal of Cardiology

1 August 2017

1 reference

1 August 2017

87

1 reference

1 August 2017

12A

1 reference

1 August 2017

19D-27D

1 reference

The ankle brachial index independently predicts walking velocity and walking endurance in peripheral arterial disease.

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Leg symptoms, the ankle-brachial index, and walking ability in patients with peripheral arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Exercise for intermittent claudication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

The pentoxifylline experience: exercise testing reconsidered

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Lower-extremity arterial disease: tips on diagnosis and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Conservative management of intermittent claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Exercise therapy for claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Exercise testing and exercise rehabilitation for patients with peripheral arterial disease: status in 1997.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Hospital vs home-based exercise rehabilitation for patients with peripheral arterial occlusive disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Exercise training improves functional status in patients with peripheral arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

The measured effect of stopping smoking on intermittent claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

The peripheral vascular consequences of smoking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Pharmacologic management of peripheral vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Comparison of graded versus constant treadmill test protocols for quantifying intermittent claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Correlating clinical indicators of lower-limb ischaemia with quality of life.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Quality of life in patients with intermittent claudication: relationship with laboratory exercise performance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Treatment of intermittent claudication: the impact on quality of life.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Improvement of the flow properties of blood: a new therapeutical approach in occlusive arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Influence of pentoxifylline on erythrocyte deformability in peripheral occlusive arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Beneficial hemorheologic therapy of chronic peripheral arterial disorders with pentoxifylline: results of double-blind study versus vasodilator-nylidrin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Placebo controlled double blind study with pentoxifylline of walking performance in patients with intermittent claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Trental 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Effects of Flunarizine and Pentoxifylline on Walking Distance and Blood Rheology in Claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Intermittent claudication: a double-blind crossover trial of pentoxifylline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Quinapril--a new angiotensin-converting enzyme inhibitor: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Pentoxifylline for intermittent claudication. A critical review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Pharmacological approaches to the treatment of intermittent claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Effect of Cilostazol, a Cyclic AMP Phosphodiesterase Inhibitor, on the Proliferation of Rat Aortic Smooth Muscle Cells in Culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

A comparison of cilostazol and pentoxifylline for treating intermittent claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

The effect of naftidrofuryl (Praxilene) on intermittent claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Naftidrofuryl in chronic arterial disease. Results of a controlled multicenter study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Buflomedil in arterial occlusive disease: results of a controlled multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

General principles for evaluation of new interventional technologies and devices. Technology Assessment Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Reporting standards for clinical evaluation of new peripheral arterial revascularization devices. Technology Assessment Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

The effect of withdrawal of drugs treating intermittent claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Anti-inflammatory effects of pentoxifylline in claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporin A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Interaction potential and tolerability of the coadministration of cilostazol and aspirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

Proposed design for a double blinded trial to evaluate medications for treatment of intermittent claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901673-3

10.1016/S0002-9149(01)01673-3

7 January 2021

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11434896